Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMELLI X: SAR341402 Interchangeability in T1DM
NCT03874715Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2019
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Sanofi. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint at Day 112, Area Under the Plasma Concentration Versus Time Curve at Day 112 and 1 more. Started Mar 2019; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03874715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874715.